Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Bendamustine Replaces Chlorambucil As “Standard of Care” in the Treatment of Elderly Patients with Chronic Lymphocytic Leukemia in German Hematology Outpatient Centres

Wolfgang Ulrich Knauf, MD, Wolfgang Abenhardt, MD, Arnd Nusch, MD, Renate Grugel, Norbert Marschner, MD

Blood (2012) 120 (21): 4605.

https://doi.org/10.1182/blood.V120.21.4605.4605

Published: 2012

Journal Articles

Bendamustine-Rituximab (BR) Replaces R-CHOP As “Standard of Care” in the Treatment of Indolent Non-Hodgkin Lymphoma in German Hematology Outpatient Centres

Wolfgang Ulrich Knauf, MD, Wolfgang Abenhardt, MD, Arnd Nusch, MD, Renate Grugel, Norbert Marschner, MD

Blood (2012) 120 (21): 3666.

https://doi.org/10.1182/blood.V120.21.3666.3666

Published: 2012

Journal Articles

Bendamustine Induces Higher Remission Rates, Prolongs Progression Free Survival as Well as Time to Next Treatment, and Improves Overall Survival for Patients In Complete Remission without Compromising Quality of Life When Compared to Chlorambucil In First Line Treatment of Chronic Lymphocytic Leukemia

Wolfgang Ulrich Knauf, MD, Toshko Lissitchkov, MD, Ali Aldaoud, MD, Anna Marina Liberati, MD, Javier Loscertales, MD, Raoul Herbrecht, Gunnar Juliusson, MD, Gerhard Postner, MD, Liana Gercheva, MD, Stefan Goranov, MD, Martin Becker, MD, Hans-Joerg Fricke, MD, Françoise Huguet, MD, Ilaria Del Guidice, MD, Peter Klein, Karlheinz Merkle, MD, Marco Montillo

Blood (2010) 116 (21): 2449.

https://doi.org/10.1182/blood.V116.21.2449.2449

Published: 2010

Journal Articles

Bendamustine in the Treatment of Chronic Lymphocytic Leukemia -Consistent Superiority Over Chlorambucil in Elderly Patients and Across Clinically Defined Risk Groups.

Wolfgang Ulrich Knauf, MD, Toshko Lissitchkov, MD, Ali Aldaoud, MD, Anna Liberati, MD, Javier Loscertales, MD, Raoul Herbrecht, MD, Gunnar Juliusson, MD, Gerhard Postner, MD, Liana Gercheva, MD, Stefan Goranov, MD, Martin Becker, MD, Hans-Joerg Fricke, MD, Francoise Huguet, MD, Ilaria Del Giudice, MD, Peter Klein, Karlheinz Merkle, MD, Marco Montillo, MD

Blood (2009) 114 (22): 2367.

https://doi.org/10.1182/blood.V114.22.2367.2367

Published: 2009

Journal Articles

Bendamustine Versus Chlorambucil in Treatment-Naive Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL): Results of an International Phase III Study.

Wolfgang Ulrich Knauf, MD, Toshko Lissichkov, M.D., Ali Aldaoud, M.D., Raoul Herbrecht, M.D., Anna Marina Liberati, M.D., Javier Loscertales, M.D., Gunnar Juliusson, M.D., Christian Dittrich, M.D., Karlheinz Merkle, M.D.

Blood (2007) 110 (11): 2043.

https://doi.org/10.1182/blood.V110.11.2043.2043

Published: 2007

Journal Articles

Final Results of a Prospective, Non-Interventional Study on Bortezomib (Velcade®, VEL) in the Treatment of Multiple Myeloma (MM) in Office-Based Hematology Units (OBH).

Wolfgang Ulrich Knauf, MD, Burkhard Otremba, MD, Friedrich Overkamp, MD, Susanne Bammer, PhD, Ralf Angermund, MD

Blood (2006) 108 (11): 5109.

https://doi.org/10.1182/blood.V108.11.5109.5109

Published: 2006

NARROW

Bendamustine Replaces Chlorambucil As “Standard of Care” in the Treatment of Elderly Patients with Chronic Lymphocytic Leukemia in German Hematology Outpatient Centres

Bendamustine-Rituximab (BR) Replaces R-CHOP As “Standard of Care” in the Treatment of Indolent Non-Hodgkin Lymphoma in German Hematology Outpatient Centres

Bendamustine in the Treatment of Chronic Lymphocytic Leukemia -Consistent Superiority Over Chlorambucil in Elderly Patients and Across Clinically Defined Risk Groups.

Bendamustine Versus Chlorambucil in Treatment-Naive Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL): Results of an International Phase III Study.

Final Results of a Prospective, Non-Interventional Study on Bortezomib (Velcade®, VEL) in the Treatment of Multiple Myeloma (MM) in Office-Based Hematology Units (OBH).

Email alerts

ASH Publications

American Society of Hematology

Bendamustine Replaces Chlorambucil As “Standard of Care” in the Treatment of Elderly Patients with Chronic Lymphocytic Leukemia in German Hematology Outpatient Centres

Bendamustine-Rituximab (BR) Replaces R-CHOP As “Standard of Care” in the Treatment of Indolent Non-Hodgkin Lymphoma in German Hematology Outpatient Centres

Bendamustine in the Treatment of Chronic Lymphocytic Leukemia -Consistent Superiority Over Chlorambucil in Elderly Patients and Across Clinically Defined Risk Groups.

Bendamustine Versus Chlorambucil in Treatment-Naive Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL): Results of an International Phase III Study.

Final Results of a Prospective, Non-Interventional Study on Bortezomib (Velcade®, VEL) in the Treatment of Multiple Myeloma (MM) in Office-Based Hematology Units (OBH).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only